Drug intelligence / Profile preview

cP12

Development stage: Phase 2
Lead developer: Neomatrix Therapeutics
Modality: Peptides, Small Molecules
Administration: Intravenous

Overview

cP12 is a drug candidate currently undergoing a Phase 2a, open-label, single-dose clinical study for the treatment of thermal burns. The trial aims to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of cP12 in adult subjects with up to 5% total body surface area burns. The drug is administered via intravenous (IV) infusion.

Targets

PDGF (Platelet-derived Growth Factor family)

Beyond the preview

Go deeper on cP12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cP12.

Explore the full profile